Theravance Biopharma (NASDAQ:TBPH) Downgraded by Wall Street Zen to Buy

Wall Street Zen cut shares of Theravance Biopharma (NASDAQ:TBPH) from a strong-buy rating to a buy rating in a report issued on Monday.

A number of other equities analysts have also recently weighed in on TBPH. BTIG Research restated a “buy” rating and set a $21.00 price objective on shares of Theravance Biopharma in a research report on Friday, March 20th. TD Cowen upped their price objective on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, March 23rd. B. Riley Financial restated a “neutral” rating and set a $14.00 price objective (down from $28.00) on shares of Theravance Biopharma in a research report on Wednesday, March 4th. Weiss Ratings upgraded shares of Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, March 24th. Finally, Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.33.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $16.10 on Monday. The company’s fifty day moving average price is $16.97 and its 200 day moving average price is $17.00. Theravance Biopharma has a 1 year low of $7.90 and a 1 year high of $21.03. The company has a market capitalization of $828.99 million, a PE ratio of 7.93 and a beta of 0.17.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the sale, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds have recently modified their holdings of TBPH. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Theravance Biopharma in the third quarter valued at about $10,611,000. Assenagon Asset Management S.A. raised its position in shares of Theravance Biopharma by 1,629.4% in the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after buying an additional 390,735 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in shares of Theravance Biopharma in the fourth quarter valued at about $6,342,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Theravance Biopharma in the third quarter valued at about $4,536,000. Finally, Janus Henderson Group PLC raised its position in shares of Theravance Biopharma by 214.8% in the fourth quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock valued at $7,493,000 after buying an additional 273,288 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.